Central Pacific Bank Trust Division Sells 300 Shares of Haemonetics Co. (NYSE:HAE)

Central Pacific Bank Trust Division cut its position in Haemonetics Co. (NYSE:HAE) by 10.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,465 shares of the medical instruments supplier’s stock after selling 300 shares during the period. Central Pacific Bank Trust Division’s holdings in Haemonetics were worth $192,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans increased its holdings in shares of Haemonetics by 6,573.6% during the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier’s stock valued at $70,267,000 after acquiring an additional 836,623 shares in the last quarter. FMR LLC increased its stake in Haemonetics by 206.3% during the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after purchasing an additional 521,640 shares in the last quarter. Wellington Management Group LLP raised its holdings in Haemonetics by 9.5% during the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock worth $337,722,000 after buying an additional 363,702 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Haemonetics by 75.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier’s stock valued at $63,933,000 after buying an additional 343,214 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Haemonetics by 327.0% during the second quarter. The Manufacturers Life Insurance Company now owns 307,564 shares of the medical instruments supplier’s stock valued at $25,445,000 after buying an additional 235,535 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Bank of America began coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 price target on the stock. BTIG Research started coverage on shares of Haemonetics in a research report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target for the company in a research report on Friday, November 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $112.00 target price on shares of Haemonetics in a research note on Tuesday, December 3rd. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $108.78.

Haemonetics Trading Up 2.1 %

Shares of HAE opened at $80.05 on Friday. The business’s 50-day moving average price is $81.93 and its 200-day moving average price is $80.78. The stock has a market cap of $4.02 billion, a PE ratio of 33.22, a P/E/G ratio of 1.26 and a beta of 0.41. Haemonetics Co. has a twelve month low of $70.25 and a twelve month high of $97.97. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. During the same period in the prior year, the company earned $0.99 EPS. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. On average, equities analysts forecast that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.